Chen S B
Changzheng Hospital, Second Military Medical College, PLA.
Zhonghua Zhong Liu Za Zhi. 1990 Jan;12(1):58-60.
Serum carbohydrate antigen CA 19-9 level was measured by radioimmunoassay in 55 patients with malignant digestive disease (14 esophageal cancers, 11 gastric cancers, 5 colorectal cancers, 14 primary liver cancers and 11 pancreatic cancers). The mean value of serum CA 19-9 levels was 22.11 +/- 24.79 u/ml in esophageal cancer, 99.91 +/- 100.12 u/ml in gastric cancer, 64.5 +/- 53.43 u/ml in colorectal carcinoma, 47.81 +/- 68.62 u/ml in primary hepatic cancer and 459.55 +/- 696.76 u/ml in pancreatic cancer (CA 19-9 greater than 37 mu/ml as positive). There were significant differences (P less than 0.05) between the mean serum CA 19-9 levels of pancreatic cancer and esophageal cancer, primary hepatic cancer. An increased CA 19-9 synthesis and excretion by tumor cells or increased pressure on pancreatic duct by the tumor may cause the elevation of serum CA 19-9 level in cancer patients. The authors conclude that CA19-9 is a valuable tumor marker in the diagnosis of pancreatic cancer and, probably, other gastrointestinal tumors.
采用放射免疫分析法检测了55例恶性消化系统疾病患者（14例食管癌、11例胃癌、5例结直肠癌、14例原发性肝癌和11例胰腺癌）的血清糖类抗原CA 19-9水平。食管癌患者血清CA 19-9水平的平均值为22.11±24.79 u/ml，胃癌为99.91±100.12 u/ml，结直肠癌为64.5±53.43 u/ml，原发性肝癌为47.81±68.62 u/ml，胰腺癌为459.55±696.76 u/ml（以CA 19-9大于37 μ/ml为阳性）。胰腺癌患者血清CA 19-9的平均水平与食管癌、原发性肝癌患者之间存在显著差异（P<0.05）。肿瘤细胞合成和分泌CA 19-9增加或肿瘤对胰管的压力增加可能导致癌症患者血清CA 19-9水平升高。作者得出结论，CA19-9是诊断胰腺癌以及可能的其他胃肠道肿瘤的有价值的肿瘤标志物。
